Avacta Group plc has announced that its proprietary pre|CISION® platform has been shortlisted for the AIM Technology of the Year Award.
The AIM Awards, which recognise the achievements of some of the world’s fastest-growing publicly quoted companies, will be held in London on 1 October 2025.
Avacta’s pre|CISION® technology is designed to transform the delivery of potent cancer therapies. By selectively targeting cancer cells while sparing healthy tissue, the platform aims to improve treatment outcomes while maintaining patients’ quality of life.
Christina Coughlin, CEO of Avacta, commented:
“We are delighted to be on the shortlist for Technology of the Year among companies listed on the AIM market. Our pre|CISION® technology changes the way that potent cancer therapies are delivered to patients, where the drug is silent in the bloodstream yet active in the tumor, allowing cancer cells to be targeted while preserving patient vitality. We look forward to the event next month.”
